Compare Pfizer Inc (PFE) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Uranium Energy Corp — how do they compare? Pfizer Inc trades at $27.77 (market cap $159.59B), while Uranium Energy Corp trades at $9.25 (market cap $4.69B). The key difference: Pfizer Inc is far larger — about 34× Uranium Energy Corp's market cap, and Pfizer Inc pays a 6.14% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Uranium Energy Corp for 37 Days on average.
| PFE | UEC | |
|---|---|---|
Market Cap | $159.59B | $4.69B |
Volume | 30,937,010 | 8,957,476 |
Sector | Health | Energy |
52-Week High | $29.02 | $20.14 |
52-Week Low | $23.67 | $9.04 |
Typical Hold Time | 158 Days | 37 Days |
Enterprise Value | $211.09B | $4.20B |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Uranium Energy (UEC) trades at $9.47, down 6.33% today, amid bearish technical signals despite strong analyst support. The company reported fiscal 2026 revenue of $37M with a net loss of $137M, reflecting operational expansion but negative profitability. Recent news highlights UEC's transition to a multi-mine producer with improved production scale and a $93.13 realized uranium price, though earnings quality concerns persist due to inventory-driven revenue.
UEC presents a high-risk, high-reward opportunity with Wall Street optimism (87.5% buy ratings, $16.06 consensus target) contrasting weak fundamentals. Key risks include sustained losses, unproven production sustainability, and uranium price volatility. The stock's upside depends on successful execution of U.S. uranium production ramp-up amid growing nuclear demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
